Practice
Featured experience
Chime $993.6 million IPO
The shares are listed on the Nasdaq Global Select Market
Cipher Mining 300 MW, $5.5 billion lease agreement with Amazon Web Services
We advised Cipher Mining on the transaction
Diameter Capital Partners $4.5 billion fundraise for its third dislocation fund
We advised Diameter on the transaction
Banco Santander $12.2 billion acquisition of Webster Bank
We are advising Banco Santander on the transaction
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
Quicken Loans $2 billion notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
Quicken Loans $2 billion notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by…
Prime Impact Acquisition I $300 million IPO
Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
China South City $250 million high-yield notes offering and cash tender offer
Davis Polk advised the initial purchasers in connection with a $250 million Regulation S only offering by China South City…
Quicken Loans $2 billion notes offering
Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…